Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States | | 2022 |
Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry | | |
Reduced CXCR4 expression in associated with extramedullary and predicts poor survival in newly diagnosed multiple myeloma | | |
Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma | | 2022 |
Myeloma precursor disease (MGUS) among rescue and recovery workers exposed to the World Trade Center disaster | | 2022 |
Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study | | 2022 |
Safety and tolerability of lenalidomide maintenance dosing in patients with multiple myeloma post-autologous stem cell transplant | Journal of Oncology Pharmacy Practice | |
Real-world treatment patterns for patients with newly diagnosed multiple myeloma in Alberta, Canada | Leukemia and Lymphoma | |
What’s Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma | Targeted Oncology | |
Monoclonal gammopathy detection and current technologies | | 2022 |
Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma | Blood Reviews | 2022 |
Baseline peripheral neuropathy was associated with age and a prognostic factor in newly diagnosed multiple myeloma patients | Scientific Reports | 2022 |
Convenient Access to Expert-Reviewed Health Information via an Alexa Voice Assistant Skill for Patients With Multiple Myeloma: Development Study | JMIR Cancer | 2022 |
Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: a retro‐prospective observational study | European Journal of Haematology | |
Converting a drug from off‐label to on‐label use: Government subsidies and patient welfare | Decision Sciences | |
Melflufen for the treatment of multiple myeloma | Expert Review of Clinical Pharmacology | |
Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma | Journal of Oncology Pharmacy Practice | |
Suprasellar Plasmacytoma Leading to the Diagnosis of Multiple Myeloma | Cureus | 2022 |
Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie’s choice for patients with relapsed refractory multiple myeloma | Expert Review of Hematology | |
Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma. | Future Oncology | 2022 |
Increasing genomic discovery in newly diagnosed multiple myeloma: defining disease biology and its correlation to risk. | Annals of Hematology | 2022 |
Healthcare Costs of Multiple Myeloma Patients with Four or More Prior Lines of Therapy, Including Triple-Class Exposure in the United States. | Oncology and Therapy | 2022 |
Diagnostic Applications of Nuclear Medicine: Multiple Myeloma | | 2022 |
Hematological Diseases | | 2022 |
Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma. | PLoS ONE | 2022 |
Demographic differences among patients treated with chimeric antigen receptor T-cell therapy in the United States. | Cancer Medicine | 2022 |
Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies. | Leukemia and Lymphoma | 2022 |
Host-microbe interactions and outcomes in multiple myeloma and hematopoietic stem cell transplantation. | Cancer and Metastasis Reviews | 2022 |
Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis. | Blood Cancer Journal | 2022 |
Data_Sheet_1.pdf | | 2020 |
Long term survival in multiple myeloma: a single institution experience in underprivileged circumstances. | Leukemia and Lymphoma | 2021 |
Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed/refractory multiple myeloma. | Supportive Care in Cancer | 2022 |
Therapy-related myeloid neoplasms following treatment for multiple myeloma-a single center analysis. | Annals of Hematology | 2022 |
Case Report: Cavernous Sinus Syndrome as the Initial Presentation of Multiple Myeloma | | 2022 |
Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database. | Clinical Lymphoma, Myeloma and Leukemia | 2022 |
Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugs | | |
A Review of Propylene Glycol-free Melphalan Conditioning for Hematopoietic Cell Transplantation for Multiple Myeloma and Light Chain Amyloidosis. | Transplantation and Cellular Therapy | 2022 |
Myeloma-Related Hypercalcemia and Bone Disease | Contemporary Endocrinology | 2022 |
Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients. | Leukemia | 2022 |
Incidence of corneal adverse events in patients with multiple myeloma and their clinical and economic impact: a real-world retrospective cohort study. | Journal of Medical Economics | 2022 |
Management of Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Novel Combination Therapies in Routine Clinical Practice in Germany. | Advances in Therapy | 2022 |
Utilization of CRISPR-Mediated Tools for Studying Functional Genomics in Hematological Malignancies: An Overview on the Current Perspectives, Challenges, and Clinical Implications. | Frontiers in Genetics | 2021 |
The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma. | Journal of Oncology Pharmacy Practice | 2022 |
Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine. | Nature Reviews Clinical Oncology | 2022 |
Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams. | Frontiers in Oncology | 2021 |
An integrated approach to protein discovery and detection from complex biofluids | | |
Isatuximab: Nursing Considerations for Use in the Treatment of Multiple Myeloma | Clinical Journal of Oncology Nursing | 2021 |
Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study | BMC Cancer | 2021 |
Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma | JCI Insight | 2021 |
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients | Hematology, Transfusion and Cell Therapy | 2021 |